Trial Profile

An open-label, single-sequence three-period crossover analyzing effect of Rabeprazole, a Proton-pump Inhibitor, on the Pharmacokinetics of Dordaviprone in Healthy Adult Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dordaviprone (Primary) ; Rabeprazole
Indications Acute myeloid leukaemia; Adenocarcinoma; Breast cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Glioblastoma; Glioma; Liver cancer; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal failure; Sarcoma; Small cell lung cancer; Thyroid cancer
Focus Adverse reactions; Pharmacokinetics

30 Oct 2023 New trial record
12 Sep 2023 Results presented at the 2023 American College of Clinical Pharmacology Annual Meeting

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com